Cross-Presentation of Cell-Associated Antigens by Dendritic Cells

  • M. Larsson
  • J. F. Fonteneau
  • N. Bhardwaj
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 276)


There is a strict requirement for professional antigen-presenting cells (APCs) in the generation of immunity toward most viruses. Exogenous pathways of MHC class I-restricted antigen presentation play an important role in the generation of antiviral immunity, particularly in the immune surveillance of virus-infected tissues of nonhematopoietic origin, and to bypass the detrimental effects of direct virus infection on professional APCs. The mechanisms underlying generation of antiviral immunity under these circumstances are discussed.


Dendritic Cell Measle Virus Human Dendritic Cell Exogenous Antigen Bone Marrow Chimera 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Albert ML, Jegathesan M, Darnell RB: Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001, 2: 1010–1017.PubMedCrossRefGoogle Scholar
  2. Albert ML, Pearce SFA, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N: Immature dendritic cells phagocytose apoptotic cells via avb5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 1998a, 188:1359– 1368.Google Scholar
  3. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998b, 392: 86–89.PubMedCrossRefGoogle Scholar
  4. Arrode G, Boccaccio C, Lule J, Allart S, Moinard N, Abastado JP, Alam A, Davrinche C: Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells. J Virol 2000, 74: 10018–10024.PubMedCrossRefGoogle Scholar
  5. Bachmann MF, Lutz MB, Layton GT, Harris SJ, Fehr T, Rescigno M, Ricciardi-Castagnoli P: Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur.J. Immunol. 1996, 26: 1–7.CrossRefGoogle Scholar
  6. Bennett SRM, Carbone FR, Karamalis F, Flavell RA, Miller JFAP, Heath WR: Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393:478– 480.Google Scholar
  7. Bennett SRM, Carbone FR, Karamalis F, Miller JJAP, Heath WR: Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Med. 1997, 186: 65–70.PubMedCrossRefGoogle Scholar
  8. Bevan MJ: Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 1976, 143: 1283–1288.PubMedCrossRefGoogle Scholar
  9. Blake N, Haigh T, Shaka’a G, Croom-Carter D, Rickinson A: The importance of exogenous antigen in priming the human CD8(+) T cell response: lessons from the EBV nuclear antigen EBNA1. J Immunol 2000, 165:7078–7087. High frequency of CTLs against EBNA1 was detected in the blood of EBV-seropositive donors. The authors conclude that CTL responses toward EBNA1 are initiated by an exogenous HLA class I presentation pathway, as epitopes from EBNA1 are poorly generated by the classic endogenous pathway of HLA class I presentation. Furthermore, the observation that DCs cocultured with soluble EBNA1 are able to activate EBNA1-specific CTL supports their conclusion.Google Scholar
  10. Castellino F, Boucher PE, Eichelberg K, Mayhew M, Rothman JE, Houghton AN, Germain RN: Receptor-mediated uptake of antigen/heat shock protein complexes results in Major Histocompatibility Complex class I antigen presentation via two distinct processing pathways. J. Exp. Med. 2000, 191: 1957–1964.PubMedCrossRefGoogle Scholar
  11. Daheshia M, Feldman L, Rouse B: Heres simplex virus latency and immune response. Current Opinion in Microbiology 1998, 1: 430–435.PubMedCrossRefGoogle Scholar
  12. Demkowitz WE, Jr. Littaua RA, Wang J, Ennis FA: Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J. Virol. 1996, 70: 2627–2631.Google Scholar
  13. den Haan J, Lehar S, Bevan M: CD8+ but not CD8- dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 2000, 192:1685–1696. The authors used OVA-loaded splenocytes incapable of direct MHC class I antigen presentation to identify the APC responsible for cross-presenting antigens to CTL. Whereas the CD8+ and CD8 DC subsets are equally able to acquire cellular associated components from the injected splenocytes, only the CD8+/CD11c+/DEC205+/CD4 DCs are able to cross-present OVA epitopes.Google Scholar
  14. Dhodapkar MV, Bhardwaj N: Active immunization of humans with dendritic cells. J. Clin. Immunol. 2000, 20: 167–174.PubMedCrossRefGoogle Scholar
  15. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N: Antigen specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 2001, 193: 233–238.PubMedCrossRefGoogle Scholar
  16. Engelmayer J, Larsson M, Subklewe M, Chahroudi A, Schmaljohn A, William C, Steinman RM, Bhardwaj N: Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 1999, 163:6762– 6768.Google Scholar
  17. Ferlazzo G, Semino C, Spaggiari GM, Meta M, Mingari MC, Melioli G: Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates. Int Immunol 2000, 12: 1741–1747.PubMedCrossRefGoogle Scholar
  18. Fugier-Vivier I, Servet-Delprat C, Rivailler P, Rissoan M-C, Liu Y-J, RabourdinCombe C: Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of DC and T cells. Submitted 1997.Google Scholar
  19. Hahn G, Jores R, Mocarski E: Cytomegalovirus remains latent in a common precur- sor of dendritic and myeloid cells. Proc Natl Acad Sci USA 1998, 95: 3937–3942.PubMedCrossRefGoogle Scholar
  20. Harding CV, Song R: Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molcules. J. Immunol. 1994, 153: 4925–4933.PubMedGoogle Scholar
  21. Heath WR, Carbone FR: Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 2001, 19: 47–64.PubMedCrossRefGoogle Scholar
  22. Heath WR, Kurts C, Miller JFAP, Carbone F: Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J. Exp. Med. 1998, 187: 1549–1553.PubMedCrossRefGoogle Scholar
  23. Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ: Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 2000, 96: 1857–1864.PubMedGoogle Scholar
  24. Huang AYC, Bruce AT, Pardoll DM, Levitsky HI: In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996, 4: 349–355.PubMedCrossRefGoogle Scholar
  25. Huang F-P, Platt N, Wykes M, Major JR, Powell TJ, Jenkins CD, MacPherson GG: A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J. Exp. Med. 2000, 191:435–444. In a rat model, a subset of DCs migrating to secondary lymph node from the gut were shown to contain apoptotic gut epithelial cells. These DCs are CD4OX40 and exhibit in vitro low capacity to enhance T cell proliferation compared with the other subset found in the afferent lymph (CD4+OX41+). This subset of rat DCs may represent the BM-derived APCs responsible for peripheral tolerance.Google Scholar
  26. Jenne L, Hauser C, Arrighi JF, Saurat JH, Hugin AW: Poxvirus as a vector to trans-duce human dendritic cells for immunotherapy: abortive infection but reduced APC function. Gene Ther 2000, 7: 1575–1583.PubMedCrossRefGoogle Scholar
  27. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH: Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000, 192: 1213–1222.PubMedCrossRefGoogle Scholar
  28. Kovacsovics-Bankowski M, Rock KL: A phagosome-to-cytosol pathway for exoge- nous antigens presented on MHC class I molecules. Science 1995, 267: 243–246.PubMedCrossRefGoogle Scholar
  29. Kruse M, Rosorius O, Kratzer F, Stelz G, Kuhnt C, Schuler G, Hauber J, Steinkasserer A: Mature dendritic cells infected with herpes simplex virus type I exhibit inhibited T cell stimulatory capacity. J. Virol. 2000, 74: 7127–7136.PubMedCrossRefGoogle Scholar
  30. Kurts C, Cannarile M, Klebba I, Brocker T: Cutting Edge: Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo. J Immunol 2001, 166:1439–1442. BM from transgenic mice with MHC class I expression driven selectively in DCs under the CD11c promoter was used to reconstitute irradiated transgenic mice that express membrane-bound OVA in the pancreas. An antigenspecific CD8+ T cell division, restricted only by the donor HLA allele, was observed, demonstrating that DCs were sufficient to cross-present self-antigens.Google Scholar
  31. Kurts C, Carbone FR, Barnden M, Blanas E, Allison J, Heath WR, Miller JF: CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J. Exp. Med. 1997, 186: 2057–2062.PubMedCrossRefGoogle Scholar
  32. Larsson M, Fonteneau JF, Bhardwaj N: Dendritic cells resurrect antigens from dead cells. Trends Immunol. 2001a, 22: 141–148.PubMedCrossRefGoogle Scholar
  33. Larsson M, Fonteneau JF, Lee A, Bhardwaj N: Interations of viruses with dendritic cells. In: Dendritic Cells; 2001b.Google Scholar
  34. Larsson M, Fonteneau J, Somersan S, Sanders C, Bickham K, Thomas E, Mahnke K, Bhardwaj N: Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Eur J Immunol 2001c, 31:3432–3442. The authors quantify the efficiency of human DC cross-presention of vaccinia virus-derived antigen by using an antigen-specific CD8+ CTL clone as responder cells. They show that low quantities of necrotic or apoptotic infected cells are equally efficient sources of antigen for cross-presentation. Maturation of DCs, especially with CD40L, is required to achieve efficient cross-presentation that can approach the presentation efficiency of a high quantity of exogenously added peptides.Google Scholar
  35. Lenz LL, Butz EA, Bevan MJ: Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens. J. Exp. Med. 2000, 192:1135–1142. Using a chimeric mice model, the authors show that BM-derived APCs are required to induce CTL responses against Listeria monocytogenes and vaccinia virus. Interestingly, CTL responses against LCMV can develop in the absence of BM-derived APCs, suggesting that CTL responses can be initiated by direct presentation of viral antigens by non-BM-derived cells.Google Scholar
  36. Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, Carbone FR, Heath WR: Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001, 166: 6099–6103.PubMedGoogle Scholar
  37. Lu Z, Yuan L, Zhou X, Sotomayor E, Levitsky HI, Pardoll DM: CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J. Exp. Med. 2000, 191:541–550. Using an in vitro system with DCs as APCs and CD8+ and CD4+ T cells from influenza hemagglutinin class I and II peptide-specific TCR transgenic mice, the authors show that both CD40-dependent and -independent CD4 help is required for efficient priming of CD8+ T cells. This CD40-independent CD4 help comprises direct sensitization of DCs by CD4+ T cells or CD4+ T cell-derived lymphokines.Google Scholar
  38. Machy P, Serre K, Leserman L: Class I-restricted presentation of exogenous antigen acquired by Fcgamma receptor-mediated endocytosis is regulated in dendritic cells. Eur. J. Immunol. 2000, 30: 848–857.PubMedCrossRefGoogle Scholar
  39. Maecker HT, Ghanekar SA, Suni MA, He XS, Picker LJ, Maino VC: Factors affecting the efficiency of CD8+ T cell cross-priming with exogenous antigens. J Immunol 2001, 166: 7268–7275.PubMedGoogle Scholar
  40. Menges M, Rossner S, Voigtlander C, Schindler H, Kukutsch NA, Bogdan C, Erb K, Schuler G, Lutz MB: Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 2002, 195: 15–21.PubMedCrossRefGoogle Scholar
  41. Norbury C, Princiotta M, Bacik I, Brutkiewicz R, Wood P, Elliott T, Bennink J, Yew-dell J: Multiple antigen-specific processing pathways for activating naive CD8+ T cells in vivo. J Immunol 2001, 166: 4355–4362.PubMedGoogle Scholar
  42. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV: Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993, 361: 359–362.PubMedCrossRefGoogle Scholar
  43. Ploegh HL: Viral strategies of immune evasion. Science 1998, 280: 248–253.PubMedCrossRefGoogle Scholar
  44. Pooley JL, Heath WR, Shortman K: Intravenous soluble antigen is presented to CD4 T cells by CD8(-) dendritic cells, but cross-presented to CD8 T cells by CD8(+) dendritic cells. J. Immunol. 2001, 166:5327–5330. The authors show that the three mouse spleen subsets of DCs (CD4+/CD8, CD4/CD8, and CD4/CD8+) have the same efficiency in vivo for the uptake of soluble OVA. However, after injection of soluble OVA in vivo and purification of these DCs subsets, only the CD4/CD8+ subset was able to process and present OVA epitopes to CD8+-specific T cells, whereas all three DC subsets were able to present OVA epitopes to CD4+-specific T cells with a higher efficiency of the CD8 DC subsets. The authors conclude that the CD4/CD8+ DCs are specialized to cross-present antigens to CD8+ T cells.Google Scholar
  45. Ramachandra L, Song R, Harding CV: Phagosomes are fully competent antigen-processing organelles that mediate the formation of peptide:class II MHC complexes. J. Immunol. 1999, 162: 3263–3272.PubMedGoogle Scholar
  46. Restifo N: Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr Opin Immunol 2000, 12: 597–603.PubMedCrossRefGoogle Scholar
  47. Riegler S, Herbart H, Einsele H, Brossart P, Jahn G, Sinzger C: Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J Gen Virol 2000, 81: 393–399.PubMedGoogle Scholar
  48. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S: Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nature Cell Biol. 1999, 1:362–368. The authors used a mouse splenic-derived DC line to show that only DCs and not macrophages can cross-present OVA antigen to CD8+ T cells from immune complexes. The pathway is TAP dependent and involves an active and size-dependent transport of specific antigens across endosomal membrane to the cytosol inside DCs.Google Scholar
  49. Salio M, Cella M, Suter M, Lanzavecchia A: Inhibition of dendritic cell maturation by herpes simplex virus. Eur. J. Immunol. 1999, 29: 3245–3253.PubMedCrossRefGoogle Scholar
  50. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N: Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 2000, 191: 423–434.PubMedCrossRefGoogle Scholar
  51. Servet-Delprat C, Vidalain PO, Azocar O, Le Deist F, Fischer A, Rabourdin-Combe C: Consequences of Fas-mediated human dendritic cell apoptosis induced by measles virus. J Virol 2000a, 74: 4387–4393.PubMedCrossRefGoogle Scholar
  52. Servet-Delprat C, Vidalain PO, Bausinger H, Manie S, Le Deist F, Azocar O, Hanau D, Fischer A, Rabourdin-Combe C: Measles virus induces abnormal differentiation of CD40 ligand-activated human dendritic cells. J. Immunol. 2000b, 164:1753– 1760.Google Scholar
  53. Sigal LJ, Crotty S, Andino R, Rock KL: Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999, 398:77–80. Transgenic mice expressing the human poliovirus receptor only in nonhematopoietic cells were created to assess whether BM-derived APCs are essential for viral antigen presentation. After infection with polio virus, CTLs were elicited in mice reconstituted with wild-type BM but remained undetectable in mice reconstituted with BM from TAP/ mice. This study demonstrates that nonhematopoietic cells are unable to directly initiate a immune response against poliovirus and that TAP-dependent antigen cross-presentation by bone marrow pAPCs is sufficient for the priming of poliovirus specific CTLs.Google Scholar
  54. Sigal LJ, Rock KL: Bone Marrow-derived Antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation. J. Exp. Med. 2000, 192:1143–1150. Using trans-genic mice, the authors show that cross-presentation by BM-derived APCs is required for the generation of CTL responses against LCMV and influenza antigens. A functional TAP is required to present the majority of studied epitopes. However, a TAP-independent pathway can be used by BM-derived APCs to generate certain epitopes when they are expressed in high quantities.Google Scholar
  55. Singh-Jasuja H, Toes RE, Spee P, Munz C, Hilf N, Schoenberger SP, Ricciardi-Castagnoli P, Neefjes J, Rammensee HG, Arnold-Schild D, Schild H: Cross-presentation of glycoprotein 96-associated antigens on Major Histocompatibility Complex class I molecules requires receptor-mediated endocytosis. J. Exp. Med. 2000, 191: 1965–1974.PubMedCrossRefGoogle Scholar
  56. Sotomayor EM, Borrello I, Rattis F-M, Abrams J, Staveley-O’Carroll K, Levitsky HI: Cross-presentation of tumor by bone marrow derived antigen presenting cells is the dominant mechanism in the induction of T cell tolerance during B-cell lymphoma progression. Blood 2001, 98: 1070–1077.PubMedCrossRefGoogle Scholar
  57. Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z, Fein S, Schoenberger S, Levitsky HI: Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999, 5: 780–787.PubMedCrossRefGoogle Scholar
  58. Subklewe M, Paludan C, Tsang ML, Steinman RM, Miinz C: Dendritic cells cross-present latency gene products from Epstein-Barr Virus-transformed B cells and expand tumor-reactive CD8(+) killer Tcells. J. Exp. Med. 2001, 193: 405–412.PubMedCrossRefGoogle Scholar
  59. Tabi Z, Moutaftsi M, Borysiewicz LK: Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class I-restricted cytotoxic T cell responses induced by cross-presentation of viral antigens. J Immunol 2001, 166: 5695–5703.PubMedGoogle Scholar
  60. Villadangos JA, Ploegh HL: Proteolysis in MHC class II antigen presentation: who’s in charge? Immunity 2000, 12: 233–239.PubMedCrossRefGoogle Scholar
  61. Yewdell J, Anton LC, Bacik I, Schubert U, Snyder HL, Bennink JR: Generating MHC class I ligands from viral gene products. Immunol Rev 1999a, 172: 97–108.PubMedCrossRefGoogle Scholar
  62. Yewdell JW, Norbury CC, Bennink JR: Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol 1999b, 73: 1–77.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • M. Larsson
    • 1
  • J. F. Fonteneau
    • 1
  • N. Bhardwaj
    • 1
  1. 1.The Laboratory of Molecular Neuro-OncologyThe Rockefeller UniversityNew YorkUSA

Personalised recommendations